Compare XRX & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | NVCT |
|---|---|---|
| Founded | 1906 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 240.4M |
| IPO Year | 2019 | 2021 |
| Metric | XRX | NVCT |
|---|---|---|
| Price | $2.67 | $8.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 5.1M | 45.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $5.55 |
| 52 Week High | $6.80 | $10.31 |
| Indicator | XRX | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 80.23 | 52.85 |
| Support Level | $2.40 | $8.08 |
| Resistance Level | $2.89 | $9.20 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 97.59 | 38.55 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.